

Supporting information

A novel fluorescence probe for estimation of Cysteine/Histidine in human blood plasma and recognition of endogenous Cysteine in live Hct116 cells

Upendar Reddy G.,^a Hridesh Agarwalla,^a Nandaraj Taye,^b Suvankar Ghorai,^b Samit Chattopadhyay,^{b*} Amitava Das^{a*}

^aCSIR-National Chemical Laboratory, Organic Chemistry Division, Pune-411008, India; E-mail: a.das@ncl.res.in; Tel: +91(0)2025902385; Fax: +91(0)2025902629;

^bChromatin and Disease Biology Lab; National Centre for Cell Science; Pune 411007, India, Email: samit@nccs.res.in.

Table of contents:	Page
Materials and method	S3
Synthetic scheme	S4
Synthesis and characterisation of L	S4
Synthesis and characterisation of R	S5
¹ H NMR spectra of L	S6
¹³ C NMR spectra of L	S7
Mass spectra of L	S8
Mass spectra of R	S9
Mass spectra of R with His	S10
Mass spectra of R with Cys	S11
Absorbance spectra of L , R and R in presence and absence of Cys and His	S12
Benesi-Hildebrand plot for binding studies of Cu ²⁺ towards L	S11
Benesi-Hildebrand plot for binding studies of [His] towards R	S13
Change of Emission intensity of R at 500 nm as a function of the solution pH:	S13
Spectrophotometric interference study of R with Cys in presence of various Amino Acids	S14
Spectrophotometric interference study of R with Cys in presence of various Amino Acids	S14
Detection of His in Human blood plasma	S14
Pre-treatment of the healthy human blood plasma for estimation of C _{Cys} & C _{His}	S15
Evaluation of C _{Cys} and C _{His} , in human blood plasma sample	S16
Cell culture and fluorescence imaging	S17
MTT assay for evolution of cytotoxicity of the reagent R towards Hct116 cells	S18
Lower detection of the probe R for Cys	S19
References	S20

Materials.

Dansyl chloride, Hydrazine Monohydrate (98%), Phthalic anhydride, 2-Pyridinecarboxaldehyde, Sodium triacetoxyborohydride, Copper (II) perchlorate hexahydrate, were obtained from Sigma Aldrich and were used as received. Cysteine, Histidine, Glutathione, Arginine, iso- Leucine, Proline, Methionine, Glycine, Alanine, Serine, Threonine, Tryptophan, Tyrosine, Valine, Leucine were purchased from SD Fine Chemicals in India. Solvents used for synthesis of various intermediates and final compounds were of AR grade (S.D. Fine Chemicals) and were used as received without further purification. HPLC grade (S.D. Fine Chemicals) solvents were used for various spectroscopic studies.

Analytical Methods:


^1H NMR spectra was recorded on a Bruker 500 MHz FT NMR (Model: Avance-DPX 500) using CDCl_3 as the solvent and tetra methyl silane (TMS) as an internal standard. ESI-MS measurements were carried out on a Waters QT of-Micro instrument. UV spectra's was recorded with a Shimadzu UV-3101 PC spectrophotometer; while fluorescence spectra were recorded using an Edinburgh instrument Xe 900 spectrofluorometer.

General experimental procedure for UV-Vis and Fluorescence studies:

1.0×10^{-4} M, solution of the **L** in aq. HEPES buffer: acetonitrile (96: 4 (v/v)) and **R** in pure aq.-HEPES buffer medium was prepared and stored in dark. This solution was used for all spectroscopic studies after appropriate dilution. 10 mM and pH 7.4 solution of aq. HEPES buffer was used for all spectroscopic studies unless mentioned otherwise. 1.0×10^{-2} M of amino acid solutions were prepared in 10 mM HEPES buffer (pH 7.4). Solution of the compound **R** was further diluted for spectroscopic titrations, and the effective final concentration of the solution of compound **R** used for the fluorescence study was 2.0×10^{-5}

M, while the final analyte concentration during emission spectral scanning was 4.0×10^{-3} M. For all luminescence measurements, $\lambda_{\text{Ext}} = 350$ nm with an emission slit width of 3 nm. The relative fluorescence quantum yields (ϕ_f) were estimated using equation 1 in acetonitrile medium by using the integrated emission intensity of dansyl amide ($\phi_f = 0.37$) for **L** and **R** as a reference.¹

Synthesis:



i. 2-Pyridine carboxaldehyde, NaBH(OAc)₃, 1,2 Dichloroethane, RT, 48 h.
 ii. Cu(ClO₄)₂·H₂O, MeOH, RT, 8h.

Scheme 1: Methodologies that were adopted for synthesis of **1**, **L** and **R**.

Synthesis of L: Synthetic procedure that was adopted for synthesis of **1** from our previous literature.¹


Synthesis of L²: Compound **1** (210 mg, 0.625 mmol) and 2-Pyridinecarboxaldehyde (401 mg, 3.75 mmol) were dissolved in 7 ml of 1, 2 dichloromethane and refluxed it for 1 h. To this reaction mixture, Sodium triacetoxyborohydride (791 mg, 3.75 mmol) in 1,2 dichloromethane (10mL) was added. The reaction mixture was allowed to stirring at room temperature for 48 h. Progress of the reaction was monitored by checking the TLC and stopped when no further change was observed. The reaction mixture was treated with saturated aqueous sodium bicarbonate solution and subsequent extraction using chloroform was performed. The organic layer was recovered, dried over anhydrous Na₂SO₄ and concentrated under reduced pressure. The crude product was subjected to neutral alumina gel

chromatography using chloroform: methanol (99.5: 0.5, v/v) as eluent. Major fraction was collected and dried under vacuum, which afforded a sticky oil solid.

Yield: 270 mg, 61.78 %. ESI- Ms (m/z) calculated for $C_{40}H_{44}N_8O_2S$: 700, observed: 701 [$M + H^+$]. 1H NMR [500 MHz, $CDCl_3$: δ (ppm)]: 8.46 (5H, d, $J = 4.0$ Hz, ArH); 8.18 (1H, d, $J = 8.5$ Hz, ArH); 8.10 (1H, d, $J = 6.5$ Hz, ArH); 7.59 (4H, t, $J = 8.0$ Hz, ArH); 7.47-7.44 (1H, m, ArH); 7.39 (5H, t, $J = 12$ Hz, ArH); 7.15-7.10 (5H, ArH); 3.67 (8H, s, CH_2); 3.39 (4H, t, $J = 7.0$ Hz, CH_2); 2.77 (6H, s, CH_3); 2.54 (4H, t, $J = 7.0$ Hz, CH_2). ^{13}C NMR (500 MHz, $CDCl_3$, δ (ppm)): 173.60, 164.71, 161.18, 145.80, 138, 137, 135.17, 129, 127.74, 124.24, 119, 50.24, 40.17, 32 and 31.60.


Synthesis of R^3 : The compound L (120 mg, 0.17 mmol) was dissolved in 7.5 mL methanol, to this $Cu(ClO_4)_2 \cdot 6H_2O$ (126 mg, 0.342 mmol) was added. Solution colour was changed immediately. The reaction mixture was stirred for 8 h and then transferred into a beaker and allowed to evaporation at room temperature to precipitate the desired compound. Light bluish white solid compound was isolated through filtration and was further carefully washed with cold Dichloromethane. Yield 120 mg, 42.25%. ESI- Ms (m/z) calculated for $C_{40}H_{44}Cu_2N_8 \cdot 2H_2O$: 862, observed: 863 [$M+H^+$].

^1H NMR spectra of **L**




SI Figure 1: ^1H NMR spectra of **L** in CDCl_3 medium.

¹³C NMR Spectra of L




SI Figure 2: ¹³C NMR spectra of L in CDCl₃ medium.

Mass spectra of L




SI Figure 3: ESI- Ms spectrum of L in CH₃OH.

Mass spectra of R




SI Figure 4: ESI- Ms spectrum of R in H₂O.

Mass spectra of R with His




SI Figure 5: ESI- Ms spectrum of **R** with His in H₂O.

Mass spectra of R with Cys




SI Figure 6: ESI- Ms spectrum of **R** with Cys in H₂O.

Absorbance spectra of L, R and R in absence and presence of Cys and His




SI Figure 7 (a) Absorbance spectra of **L** (2.0×10^{-5} M) and **R** (2×10^{-5} M) (b) Absorbance spectra of **R** (2.0×10^{-5} M) in presence of His and Cys were performed in aq HEPES buffer medium (10 mM, pH 7.4).

Benesi-Hildebrand plot for binding studies of Cu^{2+} towards L




SI Figure 8 (a) BH plot of **L** (2×10^{-5} M) for varying $[\text{Cu}^{2+}]$ (0 to 4.6×10^{-5} M) $\lambda_{\text{ext}} = 350$ and $\lambda_{\text{Mon}} = 552$ nm. Good linear fit confirms the 1: 2 binding stoichiometry in aq.-HEPES buffer- CH_3CN (96: 4(v/v); 10mM, pH 7.4) medium. (b) Luminescence titration profile.

Benesi-Hildebrand plot for binding studies of [His] towards R




SI Figure 9. Benesi-Hildebrand plot of R (2×10^{-5} M) for varying [His] (0 to 3.2×10^{-3} M) $\lambda_{Ext} = 350$ and $\lambda_{Mon} = 552$ nm. Good linear fit confirms the 1: 2 binding stoichiometry in aq.-HEPES (10 Mm, pH 7.4) medium.

Change of Emission intensity of R at 500 nm as a function of the solution pH




SI Figure 10. Change in emission intensity at 500 nm with variation in pH of the solution for R (20 μ M) by using 10 mM HEPES buffer $\lambda_{Ex} = 350$ nm.

Interference study for interaction of Cys with R in presence of various Amino Acids (AAs)




SI Figure 11. Spectrophotometric interference study of **R** ($2 \times 10^{-5} \text{M}$) with Cys ($2.8 \times 10^{-3} \text{M}$) in presence of various metal ions ($2.8 \times 10^{-3} \text{M}$) in HEPES buffer by using $I_{\text{Ext}} = 350$ and $I_{\text{Mon}} = 552 \text{ nm}$.

Interference study for interaction of His with R in presence of various AAs



SI Figure 12. Spectrophotometric interference study of **R** ($2 \times 10^{-5} \text{M}$) with His ($3.2 \times 10^{-3} \text{M}$) in presence of various metal ions ($3.2 \times 10^{-3} \text{M}$) in HEPES buffer by using $I_{\text{Ext}} = 350$ and $I_{\text{Mon}} = 552 \text{ nm}$.

Detection of His in human blood plasma



SI Figure 13. Plot of $DI = (I_0 - I)$ vs. $[His]$, where I_0 and I are emission intensities of receptor **R** at 552 nm ($\lambda_{Ext} = 350$ nm) in presence of known $[His]$ and blood plasma samples spiked with a known $[His] + 10$ mM NEM.


Pretreatment of the healthy human blood plasma for estimation of C_{Cys} & C_{His}

Fresh and human blood samples (5 mL) with added Lithium anticoagulant were centrifuged in a vacutainer tube at 3000 rpm for 15 min. The supernatant solution (plasma), which contains proteins and amino acids, was collected. 2 ml of collected plasma was vigorously mixed with appropriate amount of $NaBH_4$ and incubated for 5 minutes at room temperature in order to hydrolyse the disulphide bond. Proteins present in the sample after reduction were precipitated by the addition of methanol, followed by centrifugation (18 500g) of the sample for 15 minutes. The supernatant liquid, which contained Cys and His in blood plasma, was used for the spectroscopic studies.

Evaluation of C_{Cys} and C_{His} in human blood plasma sample

Methodology 1:

Calculation of the C_{His} in Human Blood Plasma (HBP) sample that contains Cys and His. To the 20 μM HBP sample 10 mM NEM was added. NEM is known to react irreversibly with Cys and yield a non fluorescent compound (Scheme 2 shown below). Then this resultant solution was used for quantitative analysis of His.



Scheme 2

Concentration of His in HBP is low and thus to avoid any error in its detection, HBP samples (pre-treated with excess NEM) were spiked with two known concentration of His (100 μM and 200 μM , respectively). Thus fluorescence intensity of such HBP samples spiked with 200 and 300 μM of His were $I_{\text{HBP}+200}$ and $I_{\text{HBP}+300}$, respectively. Fluorescence intensities for pure aqueous HEPES buffer solution having pH of 7.4 was evaluated for [His] of 200 and 300 μM and these values were I_{200} and I_{300} , respectively.

Thus, the difference between $I_{\text{HBP}+200}$ and I_{200} should lead to the actual concentration of His ([His]₁) in HBP sample.

Similarly, the difference between $I_{\text{HBP}+300}$ and I_{300} should lead to the actual concentration of His ([His]₂) in HBP sample.

Arithmetic mean of [His]₁ and [His]₂ led us to the value ((23 \pm 2.1) μM) for C_{His} in HBP sample. Please note that the data reported for C_{His} is an average of three independent evaluations for [His]₁ and [His]₂.


Emission intensity measurements for HBP samples treated with the reagent R directly gave the summation of concentration of C_{Cys} and C_{His} ($C_T = C_{Cys} + C_{His}$).

Thus, $C_T - C_{His} = C_{Cys}$.

Methodology 2:

C_{Cys} was also evaluated from the experiments with NEM, that reacted specifically with Cys. Emission intensity for HPB samples treated with R was evaluated (I_T), which reflects the total concentration of Cys and His present in HBP sample. Then this solution was treated with NEM. NEM reacted with Cys present in HBP sample and the product was non emissive. The emission intensity (I_{NEM}) for the resulting solution was evaluated and the difference in intensities ($DI = I_T - I_{NEM}$) was used for evaluation of [Cys] in HBP sample. Value evaluated for [Cys] in HBP sample, following this methodology, agreed well with the value that was evaluated by adopting the methodology 1.


Cell culture and fluorescence imaging



SI Figure 14. Confocal laser fluorescence microscopic images of Hct116 cells treated with 10 μ M of **R** in HEPES buffer and various reagents mentioned in the Figs. iv & viii are overlay of the merged images and confirmed the intracellular fluorescence.

Hct116 cells (3×10^5) were seeded on coverslips placed in 6 well plates. After 24 hours cells were treated with **R** ($10\mu\text{M}$) for 30 minutes or pre-treated with N-Ethyl Maleimide (NEM, a thiol specific blocking reagent (1mM) for 30 minutes before adding **R** ($10\mu\text{M}$) for 30 minutes. Cells were then washed thrice with Phosphate Buffer Saline (1X PBS) and fixed with 4% PFA for 20 minutes and washed again with 1X PBS. Permeabilization of the cells was done using 0.2% Triton X 100 for 5 minutes. Again three washes were given and then coverslips mounted using Fluor shield with DAPI (Sigma) mounting medium. Nail paints was used to seal the coverslips mounted on the glass slides. Images were acquired in Olympus Fluoview Microscope.

MTT assay for evolution of cytotoxicity of the reagent R towards Hct116 cells



SI Figure 15. MTT assay to determine the cell viability percentage in Hct116 colon cancer cells. The concentration of the **R** ranges from 0.1- 500 μM and treated for 12 hours. IC_{50} has been calculated to be 200 μM .

The *in vitro* cytotoxicity of **R** on Hct116 cells (Colon cancer cell) were determined by conventional MTT (3-(4, 5-Dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide, a yellow

tetrazole) assay. Hct116 colon cancer cells (7×10^3) were seeded in each well of a 96 well plate and cultured in a 37°C incubator supplied with 5% CO_2 . Cells were maintained in DMEM medium, supplemented with 10% Fetal Bovine Serum and 100 Units of Penicillin Streptomycin antibiotics. After 24 hours the cells were treated with different concentrations of the **R** in triplicates for 12 hours. After treatment cells were added with $0.5\mu\text{g/ml}$ of MTT reagent. The plate was then incubated for 4 hours at 37°C and then later added to each well with $100 \mu\text{l}$ of Isopropyl Alcohol. The optical density was measured at 570nm using Multiskan Go (Thermo Scientific) to find the concentration of the cell inhibition. IC_{50} value has been calculated to be $200\mu\text{M}$.

The formula used for the calculation of the MTT assay for evaluation of the cell viability is as follows:

Cell viability (%) = (means of Absorbance value of treated group/ means of Absorbance value of untreated control) X 100.

Determination of detection limit:⁵

The detection limit was calculated based on the fluorescence titration. To determine the S/N ratio, the emission intensity of **R** without Cys was measured by 10 times and the standard deviation of blank measurements was determined. The detection limit (DL) of **R** for Cys was determined from the following equation:

$$\text{DL} = K * \text{Sb1}/\text{S}$$

Where $K = 2$ or 3 (we take 2 in this case);

Sb1 is the standard deviation of the blank solution;

S is the slope of the calibration curve.

From the graph we get slope = 4.85×10^4 , and Sb1 value is 0.0004

Thus using the formula we get the Detection Limit = 1.64×10^{-8} M.

i.e. **R** can detect Cys in this minimum concentration by fluorescence techniques.

References

(1) U. Reddy G, R. Lo, S. Roy, T. Banerjee, B. Ganguly and A. Das, *Chem. Commun.*, 2013, **49**, 9818. (2) U. Reddy G, P. Das, S. Saha, M. Baidya, S. K. Ghosh and A. Das, *Chem. Commun.*, 2013, **49**, 255-257. (3) M. Ikeda, A. Matsu-ura, S. Kuwahara, S.S. Lee and Y. Habata, *Org. Lett.*, 2012, **14**, 1564-1567. (4) P. Das, A. K. Mandal, U. Reddy G., M. Baidya, S. K. Ghosh, A. Das, *Org. Biomol. Chem.*, 2013, **11**, 6604-6614. (5) S.Goswami, S.Das, K. Aich, B. Pakhira, S. Panja, S. Kanti Mukherjee and S. Sarkar, *Org. Lett.*, 2013, **15**, 5412.